|
John joined the Synvista Therapeutics Board in September 2007. John is also on the Board of Directors for EpiCept Corporation since January 2006. Prior to that time he was on the Board of Directors for Maxim Pharmaceuticals (October 2004 to January 2006) until the merger completion with EpiCept. John started consulting after his retirement from Bristol-Myers Squibb (BMS) in 2002. At B-MS John was Vice President FDA Liaison & Global Strategy where for the last 14 years he directed the development and registration programs for cardiovascular metabolic dermatology and immunology programs . He also directed the worldwide GLP and GCP programs. Over his 25-year career John has directed development and registration programs in numerous therapeutic areas. A partial listing of John’s development program experience follows: Pravachol® for hyperlipidemia primary and secondary prevention of MI stroke and revascularization; Capoten® for post-MI and diabetic nephropathy; Monopril® for hypertension; Avapro for hypertension; Glucovance® for Type 2 diabetes; Glucophage XR for Type 2 diabetes; Dovonex® for psoriasis; Vaniqa® for female hirsutism; Inderal® for post-MI and Inderal LA; and Droxia® for sickle cell anemia. Four of the development programs became marketed franchises with annual sales in excess of $1 billion.
John is a member of DIA NY Academy of Sciences and the American Association for the Advancement of Science (AAAS). He received a BA in Chemistry from Rutgers University and an M.S. in Chemistry from St Joseph’s University. | 